Journal: Arthritis and Rheumatism. 2006 Nov 28;54(12):3988-3998 [E-publication ahead of print ] Authors and affiliation: Fregni F, Gimenes R, Valle AC, Ferreira MJ, Rocha RR, Natalle L, Bravo R, Rigonatti SP, Freedman SD, Nitsche MA, Pascual-Leone A, Boggio PS. Harvard Medical School, Boston, Massachusetts. PMID: 17133529
Objective: Recent evidence suggests that Fibromyalgia is a disorder characterized by dysfunctional brain activity. Because transcranial direct current stimulation (tDCS) [application of very weak electrical currents to the head] can modulate brain activity noninvasively and can decrease pain in patients with refractory central pain, we hypothesized that tDCS treatment would result in pain relief in patients with Fibromyalgia.
Methods: Thirty-two patients were randomized to receive sham stimulation or real tDCS with the anode centered over the primary motor cortex (M1) or the dorsolateral prefrontal cortex (DLPFC) (2 mA for 20 minutes on 5 consecutive days). A blinded evaluator rated the patient's pain, using the visual analog scale for pain, the clinician's global impression, the patient's global assessment, and the number of tender points. Other symptoms of Fibromyalgia were evaluated using the Fibromyalgia Impact Questionnaire and the Short Form 36 Health Survey. Safety was assessed with a battery of neuropsychological tests. To assess potential confounders, we measured mood and anxiety changes throughout the trial.
n Anodal tDCS of the primary motor cortex induced significantly greater pain improvement compared with sham stimulation and stimulation of the DLPFC (P < 0.0001). Although this effect decreased after treatment ended, it was still significant after 3 weeks of follow-up (P = 0.004).
n A small positive impact on quality of life was observed among patients who received anodal M1 stimulation.
n This treatment was associated with a few mild adverse events, but the frequency of these events in the active-treatment groups was similar to that in the sham group.
n Cognitive changes were similar in all 3 treatment groups.
Conclusion: Our findings provide initial evidence of a beneficial effect of tDCS in Fibromyalgia, thus encouraging further trials.